custom image

Fatty Liver Disease and Multi-System Complications

March 22-24, 2021 | 10:00AM EDT | 2:00PM UTC | 3:00PM CET*
*Program is in development and subject to change



 Attention


The live portion of this conference has concluded and all presentations are now available for purchase on demand. Registrants to the live event may access this content anytime for up to 9 months following the event.


 Free Access to On Demand Content to Scientists from Low-and Middle-Income Countries


Keystone Symposia welcomes the global scientific community and aims to connect researchers within and across disciplines to accelerate the advancement of biomedical and life sciences. This form may be used for scientists from low- and middle-income countries of all career stages to determine eligibility and request free access to scientific content presented during recent eSymposia events. If eligible, you will be sent an access code for the On Demand content of the eSymposia event(s) of interest.


Apply Here


The frequency of nonalcoholic fatty liver disease (NAFLD) has risen worldwide in parallel with the obesity epidemic; however, there are still no approved therapies. The more advanced form of the disease, non-alcoholic steatohepatitis (NASH), is associated with progressive fibrosis and an increased risk of hepatocellular carcinoma (HCC). In the last decade, genetic studies have identified new proteins that participate not only in the development of hepatic steatosis, but also disease progression to NASH, cirrhosis, and HCC. Meanwhile, research is starting to emerge describing underlying molecular pathways that mediate alterations in lipid and glucose metabolism, which leads to fat accumulation in liver. Therefore, the goals of this conference are to: 1) Explore the genetic contributions to NAFLD, and how these insights might reveal the sequence of events that cause NASH and cirrhosis; 2) Clarify the key molecular events in NAFLD and NASH, focusing on pathways that might provide therapeutic opportunities; and 3) Highlight emerging therapies for NASH. This conference comes at an opportunistic time, when several clinical trials are scheduled to conclude, providing critical data to enable scientists to refine research strategies for the future.

Apply Here for Free On Demand Access

Pricing:

Regular Registration Rate: $275 USD
Student Registration Rate: $150 USD

Deadlines:

Abstract Submission:
‣ For Short Talk Consideration: February 9, 2021
‣ For Poster Booth: March 8, 2021
ePoster / SciTalk Submission: March 11, 2021
Financial Aid Application: March 8, 2021

*Please note, abstract submission is required
in order to submit an ePoster and/or Scitalk

#VKSFattyLiver21


Financial Aid Opportunities

Graduate students and postdoctoral fellows, as well as individuals from low- and middle- income countries (all career stages) working in science and medicine related fields, are eligible to apply for a FREE registration code.

Find out more about financial aid opportunities here!


Call For Abstracts

Showcase your work to global audiences on the eSymposia platform!

Submit your abstract for the opportunity to be selected for a short talk presentation alongside field leaders on the meeting program! See Abstract Deadline for Short Talk Consideration

ePoster presenters will be provided with their own dedicated page on the event website to display their work in multiple formats and interact with meeting participants. ePoster features include:

  • Abstract
  • Poster PDF for download
  • SciTalk – up to 5 minute video presentation, available on-demand
  • Live chat function to answer audience questions in real-time
  • Contact information for private follow-up discussion

To submit your work for an ePoster presentation, and to be considered for short talk selection, go to the “Submit an Abstract” tab on the event homepage.



Program Details



Speaking at this eSymposia


Noura S. Abul-Husn

Icahn School of Medicine at Mount Sinai , USA


Kendra K. Bence

Pfizer Inc. , USA


Morris J. Birnbaum

Pfizer Inc. , USA


Chuhan Chung

Gilead Sciences , USA



Eran Elinav

Weizmann Institute of Science, Israel


Hashem B. El-Serag

Baylor College of Medicine, USA


Henry N. Ginsberg

Columbia University College of Physicians and Surgeons, USA


Daniel A. Heller

Memorial Sloan Kettering Cancer Center, USA


Helen H. Hobbs

University of Texas Southwestern Medical Center, USA


Jay D. Horton

University of Texas Southwestern Medical Center, USA


Mitchell A. Lazar

Perelman School of Medicine, University of Pennsylvania, USA


Lei Ling

NGM Biopharmaceuticals, USA


Mark A. McNiven

Mayo Clinic, USA


Lopa Mishra

George Washington University, USA


Catherine Postic

INSERM, Institut Chochin, France


Elizabeth K. Speliotes

University of Michigan, USA


Greg Steinberg

McMaster University, Canada


Tobias C. Walther

Harvard School of Public Health, USA


Hannele Yki-Järvinen

University of Helsinki, Finland


More program details will be available soon.


Subscribe to receive updates to the program for this meeting.


Email address:    




Sponsors


 

Sponsor-carousel-novo-norodisk.png

 




Additional Support



sponsor-carousel-bmgf.png

sponsor-carousel-nih-NIDDKD.png

Funding for this conference was made possible (in part) by Grant No. 1R13DK129023-01 from the National Institutes of Health. The views expressed in written conference materials or publications and by speakers and moderators do not necessarily reflect the official policies of the Department of Health and Human Services; nor does mention by trade names, commercial practices, or organizations imply endorsement by the U.S. Government.




Media-in-Kind Support


sponsor-carousel-cellpress.png

sponsor-carousel-jcb-jem.png

sponsor-carousel-embo.png

sponsor-carousel-frontiers.png

 

sponsor-carousel-scientist.png

 




#ScienceMustGoOn


This new virtual meeting format came out of difficult circumstances, but your commitment to scientific progress is what inspired us to launch Keystone eSymposia. In these virtual meetings, we are capturing the same innovative essence of our in-person meetings that you've all created as a scientific community. Here, Debbie Johnson, our CEO, explains how we're going to do that.







The views expressed in this eSymposia are those of the participants and not necessarily of the participants’ organizations or of Keystone Symposia.






Donate to Keystone Symposia


custom image